According to a recent medical journal article, acute renal failure (ARF), or kidney failure, is reported as an adverse drug reaction 5.7 times more frequently with Uloric (febuxostat) than with other urate-lowering therapy (ULT) gout drugs, and 3.3 times more often with allopurinol. This is some important new Uloric drug safety information from our … [Read more...]
New Heartburn Drugs Study Shows 33% Increased Risk of Kidney Problems
Previous Research on PPIs & Kidney Damage Several studies have been published in the past several years concerning the relationship between chronic kidney disease (CKD) and proton pump inhibitors (PPIs) such as Nexium, Prilosec, and Prevacid. The table below identifies the year, title, and results of three recent studies on PPIs and kidney … [Read more...]
Could Invokana have been the cause of my lower-limb amputation?
The FDA is investigating a connection between diabetes drugs belonging to the Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors class of drugs and the following side effects: Diabetic Ketoacidosis (DKA) Ketoacidosis Ketosis Acute Kidney Injury Kidney Failure / Renal Failure Kidney Damage Pyelonephritis (kidney infection) … [Read more...]
Association Between Heartburn Drugs & Chronic Kidney Disease Questioned
A recent article published in The Journal of Allergy and Clinical Immunology titled The “dangers” of chronic proton pump inhibitor use provides commentary on the relationship between use of proton pump inhibitors (PPIs)--such as Nexium, Prilosec, and Prevacid--and various side effects. The authors of this study acknowledge the growing number of … [Read more...]
Can SGLT-2 Inhibitor Diabetes Drugs Increase Your Risk of Stroke?
While we have frequently discussed DKA, kidney damage, and amputations as possible side effects of diabetes drugs in the SGLT-2 inhibitors class -- such as Farxiga, Invokana, Jardiance -- strokes and thromboembolic events are also considered potential harmful effects of these drugs. Based on FAERS reports received during the second quarter of … [Read more...]
Nexium / Prilosec / Prevacid: Valuing Profits Over Patients
Nexium, Prilosec, and Prevacid are just a few of the popular heartburn and acid reflux drugs that have been linked with serious side effects relating to the kidneys. These drugs are manufactured by AstraZeneca (Nexium / Prilosec) and Takeda (Prevacid). Though Nexium has been marketed as substantially different and more effective than Prilosec, … [Read more...]
Federal Court Invokana MDL In New Jersey With Judge Brian Martinotti
Invokana (canagliflozin) was approved by the FDA in 2013. Invokamet (canagliflozin and metformin) was approved by the FDA in 2014. Both of these drugs were approved for use by patients with Type 2 diabetes. In December 2015 the FDA issued this Drug Safety Communication: “FDA revises labels of SGLT2 inhibitors for diabetes to include warnings … [Read more...]
Prevacid, Nexium, And Prilosec Linked To Risk Of Chronic Kidney Damage
A recent medical study done by medical researchers in St. Louis, Missouri indicates that more than half of those patients who develop chronic kidney damage (CKD) while using proton pump inhibitors (PPIs) heartburn drugs and acid reflux medicines do not experience acute kidney problems before their CKD diagnosis. These researchers published their … [Read more...]
December 2016: FDA Requires Safety Warnings Label Change For Jardiance
After the December 2, 2016 decision by the FDA decision by U.S. regulators to expand the health benefits for the relatively new diabetes medicine Jardiance (empagliflozin) to include preventing fatal heart attacks and strokes in type 2 diabetes patients, we saw news reports about its expected effect on Jardiance sales in the U.S. From this … [Read more...]
Farxiga / Jardiance / Invokana: Label Change Adds Ketoacidosis Warning
In August 2016 the FDA sent letters to Janssen Pharmaceuticals and AstraZeneca Pharmaceuticals for label changes about fatal cases of ketoacidosis cases involving Invokana (canagliflozin), Invokamet (canagliflozin and metformin), Farxiga (dapagliflozin), and Xigduo XR (dapagliflozin and metformin extended-release). As for the other diabetes … [Read more...]